Covington Guides Salix's $2.6B Gastro Drugmaker Buy

Law360, New York (November 7, 2013, 6:06 PM EST) -- North Carolina-based Salix Pharmaceuticals Ltd. struck a $2.6 billion merger deal to gobble up the gastroenterology-focused drug company Santarus Inc., to help solidify Salix's position in the niche market, the company said Thursday.

In the definitive merger agreement, Salix will cough up $32 in cash for each Santarus share in a tender offer. Santarus stock owners representing 12 percent of the company have already agreed to sell their shares, and Salix intends to use about $800 million in cash on hand, another $1.95 billion in financing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.